Nifurazolidone - General Information
A nitrofuran derivative with antiprotozoal and antibacterial activity. Nifurazolidone acts by gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
Pharmacology of Nifurazolidone
Furoxone has a broad antibacterial spectrum covering the majority of gastrointestinal tract pathogens including E. coli, staphylococci, Salmonella, Shigella, Proteus, Aerobacter aerogenes, Vibrio cholerae and Giardia lamblia. Its bactericidal activity is based upon its interference with DNA replication and protein production; this antimicrobial action minimizes the development of resistant organisms.
Nifurazolidone for patients
The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
Additional information about Nifurazolidone
Nifurazolidone Indication: For the specific and symptomatic treatment of bacterial or protozoal diarrhea and enteritis caused by susceptible organisms.
Mechanism Of Action: Nifurazolidone and its related free radical products are believed to bind DNA and induce cross-links. Bacterial DNA is particularly susceptible to this drug leading to high levels of mutations (transitions and transversions) in the bacterial chromosome.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Furazolidone
Synonyms: Nitrofurazolidone; Nitrofurazolidonum; USAF EA-1
Drug Category: Anti-Infective Agents, Local; Anti-Infective Agents, Urinary; Antitrichomonal Agents; Monoamine Oxidase Inhibitors
Drug Type: Small Molecule; Approved
Absorption: Radiolabeled drug studies indicate that furazolidone is well absorbed following oral administration
Toxicity (Overdose): Reactions to Furoxone have been reported including a fall in blood pressure, urticaria, fever, arthralgia, and a vesicular morbilliform rash. Other adverse effects can include a brown discoloration of the urine; hemolysis can occur in G6PDH-deficient patients. The drug has a monoamine oxidase (MAO) inhibitory effect and should never be given concurrently to individuals already taking MAO inhibitors.
Protein Binding: Not Available
Biotransformation: Furazolidone is rapidly and extensively metabolized; the primary metabolic pathway identified begins with nitro-reduction to the aminofuran derivative. Two major metabolites are produced: 3-amino-2-oxazolidone (AOZ) or beta-hydroxyethylhydrazine (HEH). AOZ is responsible for monoamine oxidase inhibition. Detoxification and elimination of the drug is done primarily by conjugation with glutathione.
Half Life: 10 minutes
Dosage Forms of Nifurazolidone: Tablet Oral
Chemical IUPAC Name: 3-[(5-nitrofuran-2-yl)methylideneamino]-1,3-oxazolidin-2-one
Chemical Formula: C8H7N3O5
Furazolidone on Wikipedia: https://en.wikipedia.org/wiki/Furazolidone
Organisms Affected: Microbes (bacteria, parasites)